The concentration of antibiotics obtained in the tissues on systemic administration applies only to the vascular part of the eye: the conjunctiva, sclera, choroid, and the adnexa. The avascular part of the eye, the cornea, aqueous, and vitreous present a specific ocular problem. The blood aqueous barrier keeps back penicillin and streptomycin unless they are given in high doses systemically. The eye is, in fact, as much a double organ pharmacologically as it is optically. The recorded studies on intra-ocular levels of penicillin have shown that subconjunctival injections offer the readiest means of obtaining high intra-ocular levels. Such injections are superior to the use of drops and ointments, which give but poor results, and to systemic administration which requires very high doses and gives results that compare poorly with those obtained by subconjunctival injection. If adrenaline, or other vasoconstrictors, are added to the solvent of the penicillin, the levels obtained are not only higher but more persistent. Experimentally it is possible to control any infection of the cornea, anterior chamber or vitreous caused by penicillin-susceptible organisms, if adequate doses of penicillin are administered subconjunctivally sufficiently early. An eye with panophthalmitis is beyond treatment, and clinically it is essential to learn to recognize early signs of intra-ocular infection.
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Experimentally streptomycin behaves similarly to penicillin in many respects. The white purified streptomycin at present readily available is well tolerated either as drops, ointment, or subconjunctival injection. Drops can be used in a concentration of 0-01 gramme per ml.; ointments are well tolerated up to 0 1 gramme per gramme of ointment base. Ointments are best made up by the direct incorporation of streptomycin into the ointment base without preliminary solution, and a satisfactory ointment base is 90% petroleum jelly and 10°/ liquid paraffin. Subconjunctival injections can be given to the limit of solubility: 0 5 gramme is soluble in 1 ml. water. The prolonged use of streptomycin, whether in ointment form, or as subconjunctival injections, presents some difficulties. With the ointment a rather irritative dermatitis of the lids tends to develop, whilst repeated subconjunctival injections also tend to produce local irritation. As with penicillin the addition of adrenaline to the solvent used for subconjunctival injection is of considerable help. The aqueous levels obtained with 0 5 gramme of streptomycin in 1 ml. water tend to be at a therapeutic level up to about twelve to sixteen hours. Considerably higher levels are, however, obtained when adrenaline is used as a solvent, and these levels persist up to at least thirty-six hours. The levels obtained by subconjunctival injection are considerably in excess of those obtained by intramuscular injection.
Experimental Ps. pyocyaneus infection of the cornea, which runs a disastrous course when untreated, responds very well to subconjunctival injection of 0-5 gramme streptomycin in 1 ml. adrenaline. A single injection is adequate if given within three hours of infection.
The clinical results obtained by streptomycin are discussed in some detail by Dr. Norman
Bailey. The findings are essentially:
(1) Good results in cases where a streptomycin-susceptible organism can be demonstrated -as in an isolated case of tuberculous conjunctivitis and in a series of cases of infection of the cornea due to Gram-negative bacilli. (Such infections present a characteristic picture which can be recognized clinically: instead of an infected margin there is a sloughy base with much corneal infiltration; and hypopyon need not be present. The corneal reaction is essentially a rapid melting away of tissues consistent with the proteolytic action of Gramnegative bacilli.) For corneal infections by Gram-negative organism, the method of choice would be subconjunctival injection of 0-5 gramme streptomycin in 10 minims of water and 5 minims adrenaline 1: 1,000. For tuberculous infections of the conjunctiva it is presumably better to use streptomycin systemically.
(2) Results were also good in tuberculous keratitis where the tuberculous aetiology is fairly definite.
(3) Promising results were obtained with phlyctenular ophthalmia, in which the acute attacks appeared to be cut short, and remissions made less frequent by a course of streptomycin systemically.
AUG.-OPHTHAL. 1 (4) Results were disappointing in iridocyclitis and periphlebitis of assumed tuberculous origin.
Preliminary experimental results with aureomycin and chloramphenicol suggest that intra-ocular levels from systemic administration are likely to be poor, and that better results will be obtained from subconjunctival injection. Subconjunctival injections are, however, limited by the fact that these agents are relatively insoluble, and that the preparations at present available are highly irritating. The behaviour of these two drugs, as regards absorption and excretion in the tissues, is, however, so markedly different from penicillin and streptomycin that fuller studies are essential before their use can be properly evaluated. Another difficulty with these two agents is that whilst they promise to be effective in virus lesions of the cornea, such lesions are as yet ill-understood, and cannot readily be induced experimentally. A full assessment on an experimental basis is likely to prove exceedingly difficult. Terramycin probably presents the same problems. Some clinical results with aureomycin are recorded by Dr. Ruby Joseph.
Mr. Norman L. Bailey: Streptomycin was used either systemically or locally in 48 cases at the Royal Eye Hospital and at White Oak Hospital. The cases fell into 9 clinical groups:
Tuberculous conjunctivitis.-A child with a large sloughing ulcer in the left inferior fornix, shown on biopsy to be tuberculous, was treated with intramuscular streptomycin 0 5 gramme per day for thirty days. Resolution of the lesion was rapid and uneventful, and eighteen months after treatment there was no sign of the lesion and there had been no relapse.
(Demonstrated to the Meeting.) Acute conjunctivitis due to penicillin-resistant organisms (6 cases) cleared up within forty-eight to seventy-two hours on local treatment with streptomycin by drops or ointment in concentrations between 0 05 and 0-1 gramme per ml. given at intervals varying between a half and four hours. One case was given subconjunctival injections of 0 5 gramme daily for three days.
Acute dacryocystitis due to B. proteus (one case) cleared quickly on systemic streptomycin after systemic penicillin had left it unimproved.
Infected corneal ulcer (9 cases) due to organisms resistant to penicillin responded well to daily subconjunctival streptomycin, the usual dose being 0 5 gramme in 1 ml. of fluid. All cases were left with a quiet eye except one case which was initially hopeless; 3 cases had a poor visual result of 3/60 or less, due to dense corneal scarring-2 of these had a severe infection and the other relapsed after treatment had been stopped.
The remaining cases did well visually, one case (Demonstrated) getting 6/9 and two 6/12 corrected vision. One case did not return after getting 6/36 with a mydriatic uncorrected, while a baby with ophthalmia neonatorum-who was treated with streptomycin by drops and intramuscularly-had a thin residual scar.
Tuberculous keratitis.-One case (Demonstrated), treated with intramuscular streptomycin 1 gramme per day for two months, improved from hand movements both eyes to 6/60 right eye and 6/9 left eye, corrected vision, as the bilateral active lesions settled down.
The other 2 cases treated were almost as satisfactory.
Eales' disease.-The effect of intramuscular streptomycin in 4 cases of Eales' disease was dubious and indefinite.
Iridocyclitis.-Six cases of chronic iridocyclitis suspected of being tuberculous on clinical grounds but with no definite evidence, were given intramuscular streptomycin 0 5 gramme per day for a month.
The result has been poor, with slight improvement in 4 of the cases. Phlyctenular conjunctivitis.-17 cases who did not respond to the usual treatment were given systemic streptomycin, the final dosage being 10 mg. per lb. body-weight per day for two months. The effect was good, both immediately on the active lesion and remotely in greatly reducing the frequency of the relapses.
Of the 14 active cases, 5 cases were clear within ten days and all but 2 were improved within two weeks. 5 cases had no relapses at all and 9 relapsed in the first three months. 13 cases have now been followed for between fifteen and twenty-eight months and only 2 have relapsed after the first three months following the course, when relapses were frequent; 1 of these cases is now having recurrent attacks as badly as before and 1 has had one attack lasting a month.
Post-operative intra-ocular infection.-One case, due to penicillin-resistant organisms, has retained an eye in which some useful vision may be obtained after needling.
Dr. Ruby Joseph: The 4 cases shown this afternoon represent the whole of our experience at the Royal Eye Hospital with aureomycin. 3 cases received a subconjunctival injection of 10 mg. of ophthalmic aureomycin in 1 0 ml. of solvent (containing atropine 1/40 grain, cocaine 1/8 grain, and adrenaline 5 minims). The injection was well tolerated at the time of injection, but gave considerable irritation, coming on about two hours later and persisting for several hours. Though the discomfort wore off within hours, aedema of the lids and conjunctival injection, haemorrhages, as also some mucoid discharge persisted for several days. Two of the three patients received a second injection on the 2nd and 3rd days after the first injection respectively. There was no question of giving a third injection owing to the irritative reactions.
As for the results, they may be described in these terms: (I) Disciform keratitis.-In this patient the response was good; the opacity was clearing visibly day by day. Now, four weeks after the first injection, there is little left except a fairly dense central opacity.
(2) Two cases of dendritic ulcer.-Both these cases gave a far less definite response. Staining disappeared within five days in one patient, and after two days in the second patient. In both cases the subepithelial track of the dendritic ulcer appeared to be uninfluenced. The older of these 2 cases showed a mild relapse with a dendritic ulcer a fortnight after injection. Whether either of them was influenced favourably is an open question.
Apart from these 3 cases treated with ophthalmic aureomycin, there is 1 patient with epidemic keratoconjunctivitis, first seen two davs ago. By then we had available almost pure aureomycin. She was given 10 mg. in 1 ml. of solvent two days ago. The injection was well tolerated and there were no subjective after-effects. The lids, however, were swollen twenty-four hours later, and there was a fair amount of chemosis. Today the condition is substantially the same. (Demonstrated.) It would be presumptious to draw any definite conclusions from this very limited experience. The suggestion does, however, emerge that aureomycin may prove a valuable agent in disciform keratitis, and, if suitable methods of administration become feasible, perhaps also in dendritic ulcer.
Dr. D. Ainslie: Clinical studies with aureomycin.-About eighteen months ago, when aureomycin first became available in England in reasonable quantity, it was decided to investigate its clinical properties in relation to ophthalmology. I have been fortunate in having the opportunity of examining and treating the cases so kindly referred to the Institute of Ophthalmology by surgeons of the Moorfields, Westminster and Central Eye Hospital.
Aureomycin had been tried out in the field of general medicine, both experimentally and clinically, for some time previously and it had been found to be of value against all types of coccal organism and a number of Gram-negative bacilli. Of even greater interest, however, was its reported value in dealing with a number of virus infections, rickettsial diseases, psittacosis, lymphogranuloma inguinale and primary atypical pneumonia. Accordingly it was decided to treat ophthalmological cases of infection which had failed to respond to other treatment, cases in which the causative organism was known to be insensitive to penicillin or sulphonamides and, in particular, diseases believed to be due to viruses.
So far as methods of administration go, systemic administration has been by mouth in doses of 500-750 mg. six-hourly. I have not noted any serious toxic effects. One patient developed transient vertigo and headache. Most patients have suffered a little nausea and looseness of the bowels but some have not even noticed this.
For local administration, 0 5 % aureomycin drops have proved useful for superficial infections and have given rise to no toxic effects whatever, even when given at minute intervals for an hour or more. Hourly administration for days causes no trouble. There have been reports that corneal excoriation may follow too frequent instillation, but I have not seen this occur.
The most generally useful method of topical application, particularly for outpatients, is ointment. The 5 mg. % ointment in a Eucerine base, which I used to begin with, caused a few mild allergic responses, but with the new commercial 1 mg. % ointment in wool fat and petrolatum I have had no trouble. The ointment appears to have a high antibiotic activity and latterly I have been using it more and more, in many cases in place of drops, as it is so much more convenient.
Subconjunctival injection is a feasible method of administration but so far I only have experience of injections in amounts up to I c.c. of 0.5°0 solution, i.e. 5 mg. of aureomycin. Apart from the pain of administration, which is much reduced by local aneesthetic, there has been no serious local reaction to this admittedly low concentration. One patient received six successive daily injections without damage.
2 cases of intra-ocular inflammation following operation have in fact been treated by subconjunctival injection. One infection was due to penicillin-insensitive Staph. aureus and the other to B. coli. The infections subsided following the treatment but the eyes were already considerably disorganized.
Subconjunctival injections will be discussed again in connexion with disciform keratitis.
34l
We first treated with aureomycin a series of cases of uveitis. This disease was chosen because it is so frequently unresponsive to every treatment and also because of the possible virus aetiology in some instances. In addition, there had already been a few reports from America suggesting that aureomycin might be of value. In this series, however, aureomycin was not successful.
The cases treated were of the chronic or recurrent type and were characterized by fine K.P. and, in many cases, visible cells circulating in the anterior chamber. 18 such cases have been treated and, in addition, 3 cases of recurrent hypopyon uveitis and one more in which the hypopyon uveitis was part of Behcet's syndrome. All were given oral aureomycin in doses of 500-750 mg. six-hourly over one to two weeks, in addition to local treatment. The chronic cases did not improve.
Temporary improvement, such as might be accounted for by natural remission, occurred in the cases of recurrent hypopyon uveitis but no permanent cures resulted. If indeed these cases are of virus aetiology it would therefore seem that the virus is either insensitive to aureomycin or is not reached by the antibiotic. Certainly the penetration of aureomycin into the intra-ocular fluid, when given systemically or by topical application, is very slight.
In addition to the foregoing 22 cases of uveitis, 2 cases of active sympathetic ophthalmia have failed to benefit.
However, while treatment of these cases of iridocyclitis was giving negative results, the effects of aureomycin on other diseases of more certain virus etiology were being more promising.
Trachoma.-This is almost certainly due to a virus similar to that causing psittacosis and so one would expect it to benefit. This is in fact the case. I have not been able to obtain any examples of acute stage one or early stage two trachoma, but f have treated 7 patients suffering from stage two passing into early stage three, in which cicatrization had commenced but in which there was highly active pannus-numerous sago-grain follicles and papillary hypertrophy. Further, in 3 cases it was possible to demonstrate inclusion bodies in scrapings taken from the epithelium.
All the cases responded remarkably well to aureomycin administration. All had drops and ointment locally and 3 had systemic administration as well. There was rapid clearing of the corneal ulceration, reduction in the pannus and disappearance of the papillary hypertrophy and the follicles. In 2 cases a few follicles remained but they have not altered in three months since treatment. A little vascularized pannus remains in all cases but it appears inactive. The subjective and objective improvement have been maintained in the cases over periods ranging from three to nine months after cessation of treatment.
One other case which certainly had the typical appearance of trachoma, but was peculiar in that it was unilateral and giving rise to no symptoms, and was discovered by accident, showed little or no change after a course of aureomycin. The condition remains the same today, almost a year later, and the patient is still symptom-free.
A further 5 cases of chronic trachoma have been treated with local aureomycin, with reduction in hyperemia and considerable subjective relief. The improvement has rather surprisingly continued, even after the cessation of treatment, whereas previous treatments with Albucid, penicillin, &c., had produced very transient benefit.
These findings in trachoma certainly concur well with those reported elsewhere in the world. For instance in Uganda, Boase, who has had the opportunity of treating acute cases, has had remarkable success.
The closely allied condition of follicular conjunctivitis, due to a similar though less formidable virus, is also responsive to aureomycin. 11 cases of acute and subacute follicular conjunctivitis have been treated.
It has been said that this is a self-limiting disease, but in these cases the disease had been present for from four to seven weeks without improvement despite numerous treatments.
In 2 cases there was already superficial corneal vascularization near the limbus, not in the form of trachomatous pannus but in a ring all round the cornea. In one a severe corneal ulcer had developed.
In every case improvement with aureomycin was rapid and there has been no relapse. In the first two cases I treated I gave systemic aureomycin in addition to the drops and ointment but, in view of the excellent results in the other cases with local administration alone, I doubt if this is usually necessary. In 3 cases inclusion bodies were found before treatment but none afterwards. Two additional cases of chronic conjunctivitis, with numerous small follicles and corneal vascularization, responded well to aureomycin therapy although the condition had been present for years. However, there has been a tendency towards relapse.
3 cases of chronic keratoconjunctivitis, but without follicles, contracted abroad several years previously, were treated but with only temporary success. These looked like examples of epidemic keratoconjunctivitis which had become chronic. American reports suggest that epidemic keratoconjunctivitis can be cured readily by aureomycin, but only if it is given in the early stages.
The common condition of mucopurulent conjunctivitis in infants usually responds rapidly to Albucid, penicillin or other remedies. Cultures from cases reveal from time to time a variety of pyogenic organisms, but not infrequently no organism can be cultured although there is obvious infection present.
I have seen within the last few months 8 cases of bilateral mucopurulent conjunctivitis in infants and young children which failed completely to respond to the usual measures including, in 5 cases, intensive courses of penicillin. In all cases culture was sterile or only a few colonies of Staph. albus were grown. In every case twelve hours of local aureomycin treatment produced remarkable improvement and within three to four days the condition had cleared completely, and remained cleared.
It is possible that these are examples of virus conjunctivitis, though examination of 3 of the cases has not revealed any inclusion bodies. In any case, whatever the cause, I feel that the rapid 100% results in even so short a ser;es make it well worth while bearing aureomycin in mind when dealing with infantile conjunctivitis.
One adult with mucopurulent conjunctivitis, cultures from whom grew nothing but a few colonies of Staph. albus, cleared in two days with aureomycin after penicillin had failed.
There are a number of virus diseases, however, which have not responded well to aureomycin. Herpes simplex is an example. Although 2 cases with secondary infection responded readily, 12 cases of simple acute dendritic ulcer failed completely to respond. This is in contradiction with other reports, particularly from America, where a high cure rate is claimed.
In superficial punctate keratitis temporary subjective relief was the only benefit in all of the 10 cases treated.
If systemic aureomycin is given to herpes zoster ophthalmicus in the early stages the secondary lesions appear to clear more rapidly, but I have not found that it has any beneficial effect against the iridocyclitis. 4 cases of disciform keratitis have been treated. The 2 first I treated with only topical application but there was no favourable response. The 2 latter received subconjunctival injection and improved rapidly. The corneal infiltration started to improve almost at once and continued after the cessation of injections, until the eye became entirely quiet. I hope to be able to treat further cases as the initial results are certainly encouraging.
With regard to the effects of aureomycin in the treatment of infections with simple pyogenic organisms I do not wish to say a great deal, important though these applications may be. For the action is similar to that of penicillin, though aureomycin is effective over a wider range of organisms. Many strains of Staph. aureus, for instance, are insensitive to penicillin but respond readily to aureomycin. I have treated 18 cases of blepharitis due to Staph. aureus which were insensitive to penicillin and sulphonamides when tested in vitro, and had indeed failed to respond to treatment with these drugs. Out of these 18 cases 10 have cleared up, and remain clear after over six months. 5 cleared up but have required further treatment owing to recurrences. 3 more have responded scarcely at all.
These results are approximately what one might, I think, expect, as the difficulty of completely eradicating the deep-seated organisms applies equally to aureomycin as to any other antibiotic, and a certain percentage of recurrences are inevitable. I would note, however, that 1 case now apparently cured had had the blepharitis for twenty-six years with only very temporary periods of relief, and 3 other successful cases had had the disease for six to ten years.
2 cases of blepharoconjunctivitis due to Friedldnder bacillus cleared up readily after aureomycin treatment.
In addition a number of cases of conjunctivitis from whom cultures revealed non-penicillinsensitive Staph. aureus have been successfully treated.
Thus it would seem that the outstanding value of aureomycin is in attacking a group of the large viruses but its power against the large army of non-penicillin-sensitive staphylococci and other cocci may, in the end, be its most useful application.
Systemic administration appears to be useless in infections of the globe itself but if higher concentrations of subconjunctival injections can be used (if a less irritating preparation becomes available), there seems to be hope in this direction. I should like to conclude by thanking Sir Stewart Duke-Elder for his interest and encouragement and Dr. N. Ashton for examining so many cultures and smears, and the resident staff of Moorfields, Westminster, and Central Eye Hospital, for their co-operation in dealing with in-patients.
